Atlas Trials

Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)

Clinical trial NCT05441826 · TERMINATED

Trial details

NCT number
NCT05441826
Sponsor
Tenet Medicines
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Minimal Change DiseaseFocal Segmental Glomerulosclerosis
Start date
2022-05-03
Primary completion
2023-05-03
Enrollment
1

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.